Biosimilars Market Summary

The global biosimilars market size was estimated at USD 33.92 million in 2024 and is projected to reach USD 151.58 million by 2033, growing at a CAGR of 18.27 percent from 2025 to 2033. The cost-effectiveness of biosimilar drugs and the prevalence of chronic disorders globally are major factors contributing to market growth. As patients and healthcare systems face rising treatment costs, biosimilars provide an affordable alternative to high-priced biologics, allowing wider access to essential therapies without compromising clinical effectiveness.

In addition, these drugs are comparatively easy to produce since they require less investment in research and development while providing similar therapeutic outcomes. This helps reduce overall healthcare expenditures for both patients and providers. Moreover, the reduction in production costs and increasing demand can encourage producers to shift to biosimilars due to the potential for increased profit margins, which can further boost market expansion. Although biosimilars may contain slightly different substances or combinations of medical ingredients compared to reference biologics, they are considered similar in terms of safety, quality, and efficacy based on regulatory approval standards. This ensures that patients receive reliable treatment alternatives supported by rigorous clinical evaluation.

Key Market Trends & Insights

• North America dominated the market with the largest revenue share of 42.73 percent in 2024, driven by advanced healthcare infrastructure, favorable regulatory pathways, and strong demand for cost-effective biologic treatments.
• The Asia Pacific region is expected to grow at the fastest CAGR of 19.67 percent over the forecast period, supported by expanding healthcare access, rising chronic disease incidence, and increased adoption of biosimilars in emerging economies.
• By drug class, the monoclonal antibodies segment led the market with the largest revenue share of 44.98 percent in 2024, owing to their extensive use in treating autoimmune diseases, cancers, and inflammatory conditions.
• By indication, the autoimmune disorders segment led the market with a revenue share of 39.98 percent in 2024, reflecting the high global prevalence of conditions such as rheumatoid arthritis, inflammatory bowel disease, psoriasis, and ankylosing spondylitis.
• By end use, the hospitals segment led the market with the largest revenue share of 52.09 percent in 2024, supported by increasing hospital-based administration of biologics and rising patient preference for structured clinical care settings.

Order a free sample PDF of the Biosimilars Market Intelligence Study, published by Grand View Research.

Market Size & Forecast

• 2024 Market Size: USD 33.92 Million
• 2033 Projected Market Size: USD 151.58 Million
• CAGR (2025-2033): 18.27%
• North America: Largest market in 2024
• Asia Pacific: Fastest growing market

Key Companies & Market Share Insights

The market is highly competitive, with the presence of a large number of global and local players. Since biosimilars help in the reduction of costs and lead to increased profit margins, it has encouraged new players to enter the market.

• Reddy’s Laboratories, a global pharmaceutical company, operates across four main business segments and has notably strengthened its presence in the biosimilars space through its specialized division, Dr. Reddy’s Biologics. This division is dedicated to developing and commercializing high-quality biosimilars targeting therapeutic areas such as oncology, autoimmune disorders, hematology, and nephrology.

Key Players

• Amgen Inc.
• F Hoffman-La Roche Ltd.
• Sandoz International GmbH
• Reddy’s Laboratories Ltd.
• Teva Pharmaceutical Industries Ltd.
• Pfizer Inc.
• Samsung Biopis
• Biocon
• Viatris Inc.
• Celltrion Healthcare Co., Ltd.
• AbbVie Inc.

Explore Horizon Databook – The world's most expansive market intelligence platform developed by Grand View Research.

Conclusion

The biosimilars market is expanding rapidly as healthcare systems seek affordable and effective alternatives to costly biologic therapies. With rising rates of chronic diseases and strong demand for accessible treatments, biosimilars offer a practical solution that reduces financial burden while maintaining clinical reliability. Continued regulatory support, technological advancements, and growing acceptance among healthcare providers are further accelerating adoption worldwide. Regions such as North America and Asia Pacific are playing a major role in shaping market dynamics. As production efficiencies improve and awareness increases, biosimilars are expected to contribute significantly to global healthcare sustainability in the years ahead.